Home/Filings/4/0001735276-24-000002
4//SEC Filing

Franchini Indrani Lall 4

Accession 0001735276-24-000002

CIK 0001178670other

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 4:05 PM ET

Size

13.0 KB

Accession

0001735276-24-000002

Insider Transaction Report

Form 4
Period: 2024-02-01
Franchini Indrani Lall
EVP, CLO & Secretary
Transactions
  • Exercise/Conversion

    Common Stock

    2024-02-01+5,1755,175 total
  • Sale

    Common Stock

    2024-02-02$170.01/sh502$85,3454,673 total
  • Sale

    Common Stock

    2024-02-02$171.14/sh820$140,3353,853 total
  • Sale

    Common Stock

    2024-02-02$172.38/sh269$46,3703,584 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-02-015,1755,175 total
    Common Stock (5,175 underlying)
Footnotes (6)
  • [F1]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
  • [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $169.57 to $170.57. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $170.58 to $171.54. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $171.80 to $172.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F5]Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
  • [F6]On February 1, 2022 the reporting person received 15,525 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 1, 2024, the second tranche of restricted stock units from the February 1, 2022 grant vested and was released, as reported on this Form 4.

Issuer

ALNYLAM PHARMACEUTICALS, INC.

CIK 0001178670

Entity typeother

Related Parties

1
  • filerCIK 0001708764

Filing Metadata

Form type
4
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:05 PM ET
Size
13.0 KB